NVO
NOVO NORDISK A S
NYSE: NVO · Bagsvaerd Denmark, G7 · Healthcare
$39.05-0.38 (-0.96%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$34.33 – $60.94
Avg Volume17.0M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$39.05-63.0%
Pipeline
Drug candidates sponsored by NOVO NORDISK A S · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | biphasic insulin aspart | Diabetes+1 more | Completed | 2006-08past | 2 | |
| Phase 4 | biphasic insulin aspart 30 | Diabetes+2 more | Completed | 2009-05past | 5 | |
| Phase 4 | insulin aspart | Diabetes+3 more | Completed | 2010-05past | 5 | |
| Phase 4 | semaglutide | Diabetes Mellitus, Type 2+6 more | Recruiting | 2028-09-06 | 7 | |
| Phase 3 | biphasic insulin aspart 70 | Diabetes+1 more | Completed | 1999-06past | 1 | |
| Phase 3 | insulin human | Diabetes+2 more | Completed | 2006-06past | 2 | |
| Phase 3 | Unnamed | Diabetes+3 more | Completed | 2009-06past | 1 | |
| Phase 3 | liraglutide | Diabetes+1 more | Completed | 2014-06past | 4 | |
| Phase 3 | insulin degludec/insulin aspart | Diabetes+2 more | Completed | 2017-06-01past | 2 | |
| Phase 3 | somatropin | Growth Hormone Disorder+12 more | Completed | 2018-07-12past | 6 | |
| Phase 3 | insulin degludec/liraglutide | Diabetes+1 more | Completed | 2019-06-14past | 4 | |
| Phase 3 | Semaglutide 1.0 mg | Obesity+1 more | Completed | 2020-03-24past | 1 | |
| Phase 3 | Turoctocog alfa pegol | Congenital Bleeding Disorder+1 more | Completed | 2020-12-03past | 1 | |
| Phase 3 | insulin degludec | Diabetes+3 more | Completed | 2022-01-27past | 10 | |
| Phase 3 | Insulin icodec | Diabetes Mellitus, Type 2 | Completed | 2022-06-16past | 1 | |
| Phase 3 | nonacog beta pegol | Congenital Bleeding Disorder+1 more | Completed | 2027-10-01 | 2 | |
| Phase 3 | somapacitan | Growth Hormone Disorder+2 more | Completed | 2032-12-15 | 3 | |
| Phase 2 | activated recombinant human factor VII | Acquired Bleeding Disorder+7 more | Completed | 2014-07past | 2 | |
| Phase 2 | Semaglutide 2.4 mg and NNC0165-1875 2.0 mg | Obesity | Completed | 2022-12-06past | 1 | |
| Phase 2 | NNC0487-0111 subcutanous | Type 2 Diabetes (T2D) | Completed | 2025-10-01past | 1 | |
| Phase 2 | NNC0662-0419 | Diabetes Mellitus, Type 2 | Recruiting | 2027-09-03 | 1 | |
| Phase 1 | catridecacog | Congenital Bleeding Disorder+2 more | Completed | 2003-05past | 1 | |
| Phase 1 | estradiol, 10 mcg | Menopause+1 more | Completed | 2007-05past | 1 | |
| Phase 1 | biphasic human insulin 30 | Diabetes+2 more | Completed | 2007-06past | 2 | |
| Phase 1 | 2 mg estradiol / 1 mg norethisterone acetate (NETA) | Menopause+1 more | Completed | 2007-11past | 1 | |
| Phase 1 | warfarin | Haemostasis+1 more | Completed | 2008-07past | 1 | |
| Phase 1 | NNC 0070-0002-0182 | Metabolism and Nutrition Disorder+1 more | Terminated | 2008-10past | 1 | |
| Phase 1 | insulin detemir | Diabetes+3 more | Completed | 2009-12past | 3 | |
| Phase 1 | NNC172-2021 | Congenital Bleeding Disorder+2 more | Terminated | 2012-09-04past | 1 | |
| Phase 1 | Faster-acting insulin aspart | Diabetes+1 more | Completed | 2012-09-07past | 1 | |
| Phase 1 | NNC 0148-0000-0362 | Diabetes+2 more | Completed | 2012-10past | 1 | |
| Phase 1 | sodium chloride 0.9% solution | Diabetes+3 more | Completed | 2012-10past | 1 | |
| Phase 1 | insulin 338 (GIPET I) | Diabetes+1 more | Completed | 2015-07-31past | 1 | |
| Phase 1 | NNC9204-0530 | Metabolism and Nutrition Disorder+1 more | Completed | 2017-07-07past | 1 | |
| Phase 1 | NNC0174-0833 | Obesity+1 more | Completed | 2019-06-04past | 1 | |
| Phase 1 | NNC0165-1562 | Metabolism and Nutrition Disorders+1 more | Completed | 2019-07-27past | 1 | |
| Phase 1 | Semaglutide (administered by DV3396 pen) | Overweight+1 more | Terminated | 2019-08-30past | 1 | |
| Phase 1 | NNC0363-0845 | Healthy Volunteers+1 more | Completed | 2021-06-23past | 1 | |
| Phase 1 | NNC0268-0965 | Diabetes Mellitus, Type 2 | Completed | 2021-12-10past | 1 | |
| Phase 1 | NNC0471-0119 A | Diabetes Mellitus, Type 1 | Completed | 2022-08-29past | 1 | |
| Phase 1 | Monlunabant | Obesity | Completed | 2024-10-25past | 1 | |
| Phase 1 | Cagrilintide B | Overweight+1 more | Completed | 2026-08-19past | 1 | |
| Phase 1 | Cagrilintide | Overweight+1 more | Recruiting | 2027-04-13 | 1 | |
| Phase 1 | NNC6022-0004 | Obesity+1 more | Recruiting | 2027-08-03 | 1 | |
| Phase 1 | NNC0642-1895 | Healthy Volunteers | Not yet recruiting | 2027-09-12 | 1 | |
| N/A | Unnamed | Diabetes+2 more | Completed | 2009-09past | 1 | |
| N/A | eptacog alfa (activated) | Congenital Bleeding Disorder+6 more | Completed | 2011-08past | 2 | |
| N/A | Unnamed | Diabetes+1 more | Completed | 2012-01past | 1 | |
| N/A | Unnamed | Diabetes+2 more | Completed | 2013-12-30past | 1 | |
| N/A | Insulin degludec and liraglutide (IDegLira) | Diabetes Mellitus, Type 2 | Completed | 2022-12-30past | 1 | |
| N/A | Unnamed | Obesity+1 more | Completed | 2025-10-11past | 1 | |
| N/A | Unnamed | Atherosclerotic Cardiovascular Disease+2 more | Completed | 2025-10-30past | 1 | |
| N/A | Unnamed | MASLD/MASH | Active, not recruiting | 2026-09-30past | 1 | |
| N/A | Unnamed | Pregnancy+2 more | Enrolling | 2032-10-31 | 1 | |
| N/A | Concizumab | Congenital Haemophilia | Available | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for NVO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.